The development of isozyme-specific HDAC inhibitors and a better understanding of the context-dependent effects of the individual HDAC isozymes on autophagic flux will provide more efficient options to kill cancer cells by exploiting this vulnerability in aspecifically-targeted manner. This evidence concerns the gene HDAC9 and cancer.